This approach is thought to offer potentially meaningful therapeutic benefit to patients suffering from sight-threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration.

In March 2018, the company announced positive top-line results from its Phase III trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis.